Universität zu Köln

Zaremba, Anne, Murali, Rajmohan ORCID: 0000-0001-6988-4295, Jansen, Philipp, Moeller, Inga, Sucker, Antje, Paschen, Annette, Zimmer, Lisa, Livingstone, Elisabeth, Brinker, Titus J., Hadaschik, Eva, Franklin, Cindy, Roesch, Alexander, Ugurel, Selma, Schadendorf, Dirk, Griewank, Klaus G. and Cosgarea, Ioana (2019). Clinical and genetic analysis of melanomas arising in acral sites. Eur. J. Cancer, 119. S. 66 - 77. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Full text not available from this repository.

Abstract

Study aim: Melanomas arising in acral sites are associated with a poorer prognosis than other melanoma subtypes. The aim of this study was to evaluate clinical-pathological and genetic characteristics as well as therapeutic responses of a larger cohort of patients with melanomas arising in acral sites. Methods: Clinical data of 134 patients with melanomas arising in acral sites from the Dept. of Dermatology Essen were collected and analysed with regard to clinicopathological characteristics and treatment responses. Genetic analysis with targeted next-generation sequencing was done on 50 samples. Results: In our cohort, BRAF (30%), NRAS (28%), TERT promoter (26%), NF1 (14%) and KIT (6%) were frequently identified mutations. Comparing tumours situated on palms and soles with melanomas arising on dorsal acral sites, a higher frequency of NRAS (39.1% versus 25%) and NF1 (17.3% versus 0%) and lower frequencies of BRAF (21.7% versus 75%) and TERT promoter (8.6% versus 50%) mutations were observed. MAPK activating mutations were identified in 64% of tumours. Overall survival was longer in patients treated with immune checkpoint inhibitors as first-line treatment than in patients receiving other systemic therapies (i.e. BRAF/MEK inhibitors and chemotherapy). Conclusion: Our data suggest that the genetics of melanomas arising in acral sites varies by tumour location and may influence biological behaviour. (C) 2019 Elsevier Ltd. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Zaremba, Anne UNSPECIFIED UNSPECIFIED UNSPECIFIED Murali, Rajmohan UNSPECIFIED orcid.org/0000-0001-6988-4295 UNSPECIFIED Jansen, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Moeller, Inga UNSPECIFIED UNSPECIFIED UNSPECIFIED Sucker, Antje UNSPECIFIED UNSPECIFIED UNSPECIFIED Paschen, Annette UNSPECIFIED UNSPECIFIED UNSPECIFIED Zimmer, Lisa UNSPECIFIED UNSPECIFIED UNSPECIFIED Livingstone, Elisabeth UNSPECIFIED UNSPECIFIED UNSPECIFIED Brinker, Titus J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hadaschik, Eva UNSPECIFIED UNSPECIFIED UNSPECIFIED Franklin, Cindy UNSPECIFIED UNSPECIFIED UNSPECIFIED Roesch, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Ugurel, Selma UNSPECIFIED UNSPECIFIED UNSPECIFIED Schadendorf, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED Griewank, Klaus G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cosgarea, Ioana UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-142605
DOI:	10.1016/j.ejca.2019.07.008
Journal or Publication Title:	Eur. J. Cancer
Volume:	119
Page Range:	S. 66 - 77
Date:	2019
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1879-0852
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language LENTIGINOUS MELANOMA; DISTINCT; PEMBROLIZUMAB; IPILIMUMAB; EXPRESSION; SUBTYPES; CANCER; HANDS; FEET; KIT Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14260